Key result
Bioabsorbable polymer-coated drug-eluting stents are being evaluated in clinical trials to potentially improve arterial healing and reduce late ischemic events compared to permanent polymer stents.
Why the study?
Do bioabsorbable polymer-coated drug-eluting stents improve arterial healing and reduce late ischemic events compared to permanent polymer stents?
Do bioabsorbable polymer-coated drug-eluting stents improve arterial healing and reduce late ischemic events compared to permanent polymer stents?
Answers are grounded in this paper and cite their sources.
Bioabsorbable polymer-coated DES may improve arterial healing and reduce late ischemic events by removing a chronic source of inflammation compared to permanent polymers.
Drug-eluting stents (DES) have been shown to significantly reduce clinical and angiographic restenosis compared to bare metal stents (BMS). The polymer coatings on DES elute antiproliferative drugs to inhibit intimal proliferation and prevent restenosis after stent implantation. Permanent polymers which do not degrade in vivo may increase the likelihood of stent-related delayed arterial healing or polymer hypersensitivity. In turn, these limitations may contribute to an increased risk of late clinical events. Intuitively, a polymer which degrades after completion of drug release, leaving an inert metal scaffold in place, may improve arterial healing by removing a chronic source of inflammation, neoatherosclerosis, and/or late thrombosis. In this way, a biodegradable polymer may reduce late ischemic events. Additionally, improved healing after stent implantation could reduce the requirement for long-term dual antiplatelet therapy and the associated risk of bleeding and cost. This review will focus on bioabsorbable polymer-coated DES currently being evaluated in clinical trials.
No takes yet. Share an insight, caveat, or question.
Hou et al. (2017) reported a review. Bioabsorbable polymer-coated drug-eluting stents vs. Permanent polymer drug-eluting stents was evaluated. Bioabsorbable polymer-coated drug-eluting stents are being evaluated in clinical trials to potentially improve arterial healing and reduce late ischemic events compared to permanent polymer stents.
Synapse has enriched 10 related papers. Consider them for comparative context: